1. Home
  2. INSM vs WRB Comparison

INSM vs WRB Comparison

Compare INSM & WRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • WRB
  • Stock Information
  • Founded
  • INSM 1988
  • WRB 1967
  • Country
  • INSM United States
  • WRB United States
  • Employees
  • INSM N/A
  • WRB N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • WRB Property-Casualty Insurers
  • Sector
  • INSM Health Care
  • WRB Finance
  • Exchange
  • INSM Nasdaq
  • WRB Nasdaq
  • Market Cap
  • INSM 29.0B
  • WRB 29.5B
  • IPO Year
  • INSM 2000
  • WRB N/A
  • Fundamental
  • Price
  • INSM $182.69
  • WRB $73.99
  • Analyst Decision
  • INSM Strong Buy
  • WRB Hold
  • Analyst Count
  • INSM 19
  • WRB 12
  • Target Price
  • INSM $171.12
  • WRB $73.18
  • AVG Volume (30 Days)
  • INSM 2.1M
  • WRB 3.5M
  • Earning Date
  • INSM 10-30-2025
  • WRB 10-20-2025
  • Dividend Yield
  • INSM N/A
  • WRB 2.17%
  • EPS Growth
  • INSM N/A
  • WRB 22.18
  • EPS
  • INSM N/A
  • WRB 4.76
  • Revenue
  • INSM $447,022,000.00
  • WRB $14,654,011,000.00
  • Revenue This Year
  • INSM $40.09
  • WRB $8.63
  • Revenue Next Year
  • INSM $129.64
  • WRB $6.53
  • P/E Ratio
  • INSM N/A
  • WRB $15.55
  • Revenue Growth
  • INSM 30.34
  • WRB 11.08
  • 52 Week Low
  • INSM $60.40
  • WRB $55.97
  • 52 Week High
  • INSM $197.08
  • WRB $78.48
  • Technical
  • Relative Strength Index (RSI)
  • INSM 67.29
  • WRB 49.89
  • Support Level
  • INSM $178.76
  • WRB $70.30
  • Resistance Level
  • INSM $197.08
  • WRB $75.53
  • Average True Range (ATR)
  • INSM 7.01
  • WRB 1.64
  • MACD
  • INSM 1.60
  • WRB -0.37
  • Stochastic Oscillator
  • INSM 65.96
  • WRB 66.37

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About WRB W.R. Berkley Corporation

W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.

Share on Social Networks: